bkcui 发表于 2012-6-3 17:33:04

重生 发表于 2012-6-3 20:41:30

关注。不懂。学习

bmiles 发表于 2012-6-4 15:37:23

期待,关注,学习

太阳 发表于 2012-6-5 18:10:54

顶起，都来关注

bkcui 发表于 2012-6-6 00:39:57

julie_jin 发表于 2012-6-6 01:27:13

ARQ 197，期待中!

wwdcz 发表于 2012-7-29 22:37:14

关注中 ！！！

小P 发表于 2012-7-29 23:11:18

热切期待!希望尽快能用上!!!

咪咪不怕 发表于 2012-7-30 14:24:52

想问下ARQ197和Crizotinib 比如何呢？是不是前者注重CMET，后者更注重ALK？

金刚石 发表于 2012-8-21 11:06:23

平安！ 发表于 2012-6-1 22:06 static/image/common/back.gif
ARQ197，我非常看好！主要是他是单c-met靶点，副作用极低，非常适合与EGFR、VEGFR联用。目前本论坛推荐用XL ...

BCP000861/Tivantinib/ARQ197/ARQ-197/
Brand Name :Biochempartner
MF:C23H19N3O2
MW:369.42
Purity:99%
Solubility:unknow
Surprise price with large stock
High quality with HPLC & NMR Chart
Fast delivery about 4-5 working days

CAS No: 905854-02-6       
Bulk Order Enquiry
Purchase price
Customer Feed Back:
Goods Reviews:
Biological Activity:
ARQ 197(Tivantinib) as the first non-ATP–competitive small molecule that selectively targets the c-Met receptor tyrosine kinase. Exposure to ARQ197(Tivantinib) resulted in the inhibition of proliferation of c-Met–expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity. These cellular responses to ARQ197(Tivantinib) were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ197(Tivantinib) in multiple mouse xenograft efficacy studies. Cumulatively, these data suggest that ARQ197(Tivantinib), currently in phase II clinical trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation. Mol Cancer Ther
References:
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
版主是这个吗?
页: 1 [2] 3
查看完整版本: 2012ASCO肝癌重点关注两种药物tivantinib（ARQ197）,和cabozantinib（184）